Tuberculosis Pleural Management
Introduction to Tuberculosis Pleural
- The American Thoracic Society recommends that tuberculosis pleural should be treated actively, as the risk of reactivation in individuals with radiographic evidence of previous tuberculosis is approximately 2.5 times higher compared to those with latent infection without radiographic abnormalities 2
- Historically, before effective antitubercular chemotherapy, extrapulmonary tuberculosis had high morbidity and mortality 1
Diagnosis and Evaluation
- The Centers for Disease Control and Prevention suggests that scarce fibrous tracts after a pleural effusion are more characteristic of tuberculosis pleural than common bacterial infections 3
- Typical tuberculosis leaves apical fibronodular infiltrations, frequently with volume loss and apical pleural thickening 3
- The American College of Chest Physicians recommends obtaining sputum samples for acid-fast bacillus smear and culture, even using sputum induction if necessary, as approximately 20% of patients may have persistent abnormalities representing active disease 6
Treatment and Management
- The World Health Organization recommends a 6-month regimen for tuberculosis pleural: isoniazid, rifampicin, and pyrazinamide for 2 months, followed by 4 months of isoniazid and rifampicin 1
- The Infectious Diseases Society of America suggests that if the treatment history is uncertain and there is radiographic evidence of previous tuberculosis, consider treatment of latent infection with 9 months of isoniazid 2
- The American Thoracic Society recommends against the routine use of corticosteroids for tuberculous pleural effusion, as they do not prevent long-term pleural sequelae 7
Follow-up and Monitoring
- The Centers for Disease Control and Prevention recommends clinical monitoring every 3 months during the first year after completing tuberculosis treatment 2
- The American College of Chest Physicians suggests investigating promptly any new respiratory symptoms, especially within 3 months of completing treatment 2
- The Infectious Diseases Society of America recommends regular clinical follow-up every 3-6 months during the first year, then annually 2